Galapagos GLPG5101 phase 1/2 r/r iNHL cohort differentiates with high CR rate
Galapagos presented new data from the ongoing Phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) at the International Conference on Malignant Lymphoma (ICML). Results from the r/r iNHL cohort (FL and MZL) showed a high complete response rate of 97%, higher than Yescarta's 75% CR rate (79% in FL, 75% in MZL) in the same patient population in the phase 2 (ZUMA-5) trial. Safety continues to be a differentiator with only 1 grade 3 ICANS (vs. 19% grade = 3 with Yescarta). All in all, a supportive dataset that will help conversations with strategic partners, as Galapagos has decided to explore such options for the cell therapy business. We reiterate our € 37 TP and Buy rating.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.